ERBB2 and neoplasm: Suppression of HER2 signaling was supported by ex vivo IHC analysis of tumor samples from a small subset of satellite animals (3–5 animals per group) of both the BT-474 subcutaneous model (Fig. 6B and C) and the intracranial model (Supplementary Fig. S6E).